SERES THERAPEUTICS INC's ticker is MCRB and the CUSIP is 81750R102. A total of 98 filers reported holding SERES THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.89 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,195,933 | -50.4% | 922,661 | -0.3% | 0.00% | -100.0% |
Q2 2023 | $4,431,530 | +5.5% | 925,163 | +24.9% | 0.00% | 0.0% |
Q1 2023 | $4,199,622 | +2.7% | 740,674 | +1.4% | 0.00% | 0.0% |
Q4 2022 | $4,090,519 | -13.2% | 730,450 | -0.5% | 0.00% | 0.0% |
Q3 2022 | $4,715,000 | +103.1% | 734,481 | +8.5% | 0.00% | – |
Q2 2022 | $2,321,000 | -53.5% | 676,808 | -3.4% | 0.00% | -100.0% |
Q1 2022 | $4,989,000 | -18.9% | 700,754 | -5.1% | 0.00% | 0.0% |
Q4 2021 | $6,148,000 | +29.6% | 738,155 | +8.3% | 0.00% | 0.0% |
Q3 2021 | $4,743,000 | -72.2% | 681,475 | -4.7% | 0.00% | -66.7% |
Q2 2021 | $17,055,000 | +28.9% | 715,107 | +11.3% | 0.00% | +50.0% |
Q1 2021 | $13,231,000 | -21.2% | 642,606 | -6.2% | 0.00% | -33.3% |
Q4 2020 | $16,790,000 | -9.2% | 685,317 | +4.9% | 0.00% | -25.0% |
Q3 2020 | $18,491,000 | +602.3% | 653,137 | +18.1% | 0.00% | +300.0% |
Q2 2020 | $2,633,000 | +57.1% | 553,086 | +17.8% | 0.00% | – |
Q1 2020 | $1,676,000 | +5.5% | 469,475 | +2.0% | 0.00% | – |
Q4 2019 | $1,588,000 | -16.7% | 460,114 | -3.2% | 0.00% | – |
Q3 2019 | $1,907,000 | +125.9% | 475,415 | +81.3% | 0.00% | – |
Q2 2019 | $844,000 | -51.2% | 262,269 | +4.2% | 0.00% | – |
Q1 2019 | $1,730,000 | +53.4% | 251,696 | +0.8% | 0.00% | – |
Q4 2018 | $1,128,000 | -40.9% | 249,663 | -0.7% | 0.00% | – |
Q3 2018 | $1,908,000 | -9.9% | 251,439 | +2.1% | 0.00% | -100.0% |
Q2 2018 | $2,118,000 | +24.2% | 246,310 | +6.0% | 0.00% | – |
Q1 2018 | $1,705,000 | -27.7% | 232,289 | -0.1% | 0.00% | -100.0% |
Q4 2017 | $2,358,000 | -38.1% | 232,522 | -2.1% | 0.00% | 0.0% |
Q3 2017 | $3,809,000 | +43.0% | 237,494 | +0.7% | 0.00% | 0.0% |
Q2 2017 | $2,664,000 | +16.5% | 235,766 | +16.2% | 0.00% | 0.0% |
Q1 2017 | $2,286,000 | +14.0% | 202,891 | +0.1% | 0.00% | 0.0% |
Q4 2016 | $2,006,000 | -18.3% | 202,679 | +1.5% | 0.00% | 0.0% |
Q3 2016 | $2,455,000 | -53.0% | 199,711 | +11.1% | 0.00% | -50.0% |
Q2 2016 | $5,224,000 | +115.0% | 179,822 | +96.6% | 0.00% | +100.0% |
Q1 2016 | $2,430,000 | -23.5% | 91,480 | +1.1% | 0.00% | 0.0% |
Q4 2015 | $3,175,000 | +272.7% | 90,493 | +214.9% | 0.00% | – |
Q3 2015 | $852,000 | – | 28,739 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Flagship Pioneering Inc. | 23,117,045 | $110,730,646 | 4.94% |
Lion Point Capital, LP | 691,803 | $3,313,736 | 1.50% |
Eversept Partners, LP | 3,076,756 | $14,737,661 | 1.23% |
Soleus Capital Management, L.P. | 2,045,983 | $9,800,259 | 1.09% |
Knott David M Jr | 470,000 | $2,251 | 0.90% |
GREAT POINT PARTNERS LLC | 938,067 | $4,493,341 | 0.88% |
Simplify Asset Management Inc. | 550,626 | $2,637,499 | 0.35% |
Delphia (USA) Inc. | 33,913 | $162,443 | 0.26% |
Alpha DNA Investment Management LLC | 138,536 | $663,587 | 0.22% |
Avoro Capital Advisors LLC | 2,500,000 | $11,975,000 | 0.16% |